“The prognostic value of mild cognitive impairment (MCI) is being questioned, with some MCI subjects reverting to normal cognition. The reversion rate varies mostly depending on the study design, the setting, and both MCI and normal cognition definitions. Previous studies have focused on the profile of subjects who revert to normal cognition, but the role of comorbidities has not been entirely investigated. We aimed to evaluate the proportion of MCI subjects who revert to normal cognition in a memory clinic context, focusing on the role of comorbidities. Between 2004 and 2013, 374 MCI subjects were recruited. During a mean time of 32 ± 25.5 months, 21 subjects (5.6%) reverted to normal cognition. Subjects who reverted to NC were younger, more educated, had a better global cognition, as assessed by the Mini-Mental State Examination (MMSE) and suffered from more comorbidities, as assessed by Cumulative Illness Rating Scale (CIRS) than those who developed dementia. The Cox Regression Model, constructed to adjust for the confounders, showed that the higher were the MMSE and the CIRS score at baseline, the higher was the probability of returning to normal cognition than developing dementia, though the last association was not significant. Subjects who reverted to normal cognition were more frequently affected by respiratory, urologic, and psychiatric diseases. [The authors suggest that] the cognitive performance of subjects with medical comorbidities could benefit from preventive strategies aimed at treating the underlying diseases.”
.
Grande G, Cucumo V, Cova I, Ghiretti R, Maggiore L, Lacorte E, Galimberti D, Scarpini E, Clerici F, Pomati S, Vanacore N and Mariani C: Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation. J. Alzheimers Dis. 51(1):57-67 (2016).

.
http://www.ncbi.nlm.nih.gov/pubmed/26836169